Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

Feb. 6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two ...

VERONA is a phase II trial evaluating the company's lead investigational product Duravyu in diabetic macular edema ... as measured by optical coherence tomography (OCT) and change in diabetic ...

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

Diabetic macular edema can result in low vision or vision loss. Early treatment can help preserve vision longer. Diabetic macular edema (DME) is a complication of diabetes. Over time, high blood ...

Before the advent of OCT, FA was the standard tool used to diagnosis macular edema. The finding of a ''petaloid'' pattern of late leakage is classic for the diagnosis of cystoid macular edema.

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only FDA-approved treatment shown to ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only ...

Please provide your email address to receive an email when new articles are posted on . The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet ...